NCT02228382 2021-12-30
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
Pfizer
Phase 4 Terminated
Clinical Trials
5 trialsNCT02130557 2021-05-18
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Pfizer
Phase 3 Completed
NCT02638467 2020-11-05
Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy
University of Milano Bicocca
Phase 2 Completed
NCT00261846 2017-07-27
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
Pfizer
Phase 2 Completed
NCT00777530 2008-10-23
Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 1 Completed